Semaglutide Side Effects: What to Know Before Starting Treatment

Every medication carries the possibility of side effects, and semaglutide is no exception. But the conversation around GLP-1 side effects has become muddled by social media anecdotes, worst-case headlines, and a lack of context about what the clinical data actually shows.

Here is the reality: The majority of semaglutide side effects are gastrointestinal, mild to moderate in severity, and temporary. They are most common during the initial weeks of treatment and during dose increases. With proper medical supervision and a gradual titration schedule, most patients tolerate semaglutide well — and the side effects that do occur are manageable.

This guide covers what the clinical evidence shows, what to expect at each dosing phase, how side effects are managed in a supervised setting, and what warning signs require immediate attention. If you are considering semaglutide for weight loss, understanding the full side effect profile is an essential part of making an informed decision.

Common Side Effects of Semaglutide

The STEP clinical trial program — which enrolled thousands of participants — provides the most comprehensive data on semaglutide side effects at the 2.4 mg weight loss dose. The overwhelming majority of reported adverse events fall into the gastrointestinal category.

Nausea

Nausea is the most frequently reported side effect, affecting approximately 20 to 30 percent of patients in clinical trials. It tends to be most noticeable during the first one to two weeks after starting treatment or after each dose increase.

For most patients, nausea is mild and self-limiting. It peaks during the titration phase and diminishes significantly once a stable dose is reached. Fewer than 5 percent of clinical trial participants discontinued treatment due to nausea.

Management tips: Eat smaller, more frequent meals. Avoid eating to the point of fullness. Stay hydrated with small sips of water throughout the day. Avoid greasy, fried, or heavily spiced foods during dose adjustment periods. Some patients find that eating bland, protein-rich foods helps considerably.

Constipation

Constipation occurs in approximately 10 to 15 percent of patients. Because semaglutide slows gastric emptying — part of its mechanism for reducing appetite — it can also slow transit time through the entire digestive tract.

Onset is typically gradual and can occur at any point during treatment. For most patients, it is mild and responds well to simple interventions.

Management tips: Increase water intake significantly (aim for at least 64 ounces per day). Add fiber-rich foods gradually. Gentle movement and walking after meals can help promote motility. If dietary changes are insufficient, your provider may recommend a stool softener or fiber supplement.

Diarrhea

Diarrhea affects roughly 10 to 15 percent of patients, sometimes alternating with constipation during the adjustment period. It is more common in the early weeks and tends to resolve as the body adapts.

Management tips: Stay well hydrated. Avoid dairy and high-fat foods during episodes. If diarrhea persists beyond the first few weeks at a given dose, contact your provider — a dosing adjustment may be appropriate.

Headache

Headaches are reported by approximately 10 to 14 percent of patients. They are more common during the initial phase of treatment and often correlate with changes in eating patterns, hydration status, or blood sugar levels.

Management tips: Ensure adequate hydration and consistent meal timing. Many patients find that headaches resolve once eating patterns stabilize. Over-the-counter pain relief is generally safe, but confirm with your provider.

Fatigue

Fatigue affects roughly 5 to 10 percent of patients, particularly during the first few weeks. This is partly related to reduced caloric intake as appetite decreases. The body needs time to adjust to a lower energy equilibrium.

Management tips: Prioritize sleep. Maintain adequate protein and micronutrient intake — a common mistake is allowing nutrition quality to drop alongside total calories. If fatigue is persistent, your provider should evaluate for nutritional deficiencies through diagnostic testing.

Less Common Side Effects

While the common GI side effects receive the most attention, there are several less frequent side effects that patients should understand.

Gallbladder Issues

Rapid weight loss from any cause increases the risk of gallstone formation and gallbladder-related complications. In the STEP trials, gallbladder-related events occurred in approximately 1.5 to 2.5 percent of semaglutide patients compared to about 1 percent on placebo.

Symptoms to watch for include sharp pain in the upper right abdomen, pain after eating fatty meals, nausea accompanied by abdominal discomfort, and pain radiating to the right shoulder blade. If you experience these symptoms, contact your provider promptly.

Hair Thinning

Hair thinning is not a direct pharmacological effect of semaglutide. It is a well-documented consequence of rapid weight loss from any method — surgery, caloric restriction, or medication. The condition is called telogen effluvium, where a significant metabolic change causes hair follicles to shift from the growth phase into the resting phase simultaneously.

This typically occurs two to four months after the onset of rapid weight loss. It is almost always temporary, resolving within three to six months as weight stabilizes. Ensuring adequate protein, iron, biotin, and zinc intake supports healthy hair regrowth. Patients concerned about thyroid-related factors should discuss additional screening with their provider.

Pancreatitis Warning Signs

Pancreatitis is rare but is included in the boxed precautions for all GLP-1 receptor agonists. The absolute incidence in clinical trials was low — fewer than 0.5 percent of patients.

Seek immediate medical attention if you experience: Severe, persistent abdominal pain (especially radiating to the back), persistent vomiting, or abdominal tenderness that does not resolve. These symptoms require urgent evaluation regardless of their cause.

Injection Site Reactions

Mild injection site reactions — redness, itching, or minor swelling — occur in approximately 3 to 5 percent of patients. These are usually self-limiting and rarely require treatment modification.

Management tips: Rotate injection sites between the abdomen, thigh, and upper arm. Allow the medication to reach room temperature before injection. Clean technique reduces the risk of localized reactions.

Dizziness

Dizziness is reported in approximately 5 to 7 percent of patients. It is most often related to reduced caloric intake, dehydration, or changes in blood pressure associated with weight loss.

Management tips: Rise slowly from sitting or lying positions. Ensure adequate fluid and electrolyte intake. If dizziness is frequent or severe, your provider should evaluate blood pressure and metabolic markers.

Muscle Loss During Treatment

This is one of the most important conversations in GLP-1 therapy, and it deserves a direct answer.

All significant weight loss — from any method — results in some loss of lean mass. This is not unique to semaglutide. Bariatric surgery, aggressive caloric restriction, and medication-assisted weight loss all produce a combination of fat loss and lean tissue loss.

In the STEP clinical trials, approximately 30 to 40 percent of total weight lost was lean mass. This is comparable to what is observed with dietary weight loss in the same range.

The critical variable is not whether lean mass loss occurs — it is whether you take active steps to minimize it. The two most impactful interventions are:

1. Protein intake: Aim for 0.7 to 1.0 grams of protein per pound of body weight daily. This is significantly higher than most people consume naturally and requires deliberate planning.
2. Resistance training: Consistent strength training throughout treatment sends the signal to preserve and build muscle tissue even during a caloric deficit.

Patients who combine semaglutide with adequate protein and structured resistance training retain significantly more lean mass than those who rely on the medication alone. For more on the relationship between body composition and hormonal health, see our article on building muscle with low testosterone.

At Rewind, our weight loss programs include guidance on nutrition and exercise specifically designed to protect lean mass during GLP-1 therapy.

Managing Side Effects: Practical Strategies

The difference between tolerating semaglutide well and having a difficult experience often comes down to preparation and protocol. Here are the strategies that make the most measurable difference.

Slow, structured titration. Starting at the lowest dose (0.25 mg) and increasing gradually over 16 to 20 weeks gives the body time to adapt. Rushing through titration to reach higher doses faster is the single most common cause of unnecessary side effects.

Hydration. GLP-1 medications slow gastric emptying and can alter fluid balance. Aim for a minimum of 64 ounces of water daily. Many patients benefit from electrolyte supplementation, particularly during the first few months.

Dietary adjustments. The following changes make a meaningful difference during treatment:

• Eat smaller meals more frequently rather than two or three large meals
• Prioritize lean protein at every meal
• Reduce or eliminate greasy, fried, and heavily processed foods
• Avoid carbonated beverages if they worsen bloating or nausea
• Eat slowly and stop before feeling full — the sensation of fullness on semaglutide is stronger and arrives faster
• Keep bland, easy-to-digest options available for days when GI symptoms are more pronounced

Know when to contact your provider. Mild nausea and occasional GI discomfort during titration are expected. The following warrant a call to your provider:

• Nausea or vomiting that prevents you from eating or drinking for more than 24 hours
• Severe or persistent abdominal pain
• Signs of dehydration (dark urine, dizziness, rapid heartbeat)
• Any symptom that is significantly affecting your daily functioning
• Symptoms that worsen rather than improve after two weeks at the same dose

A supervised program should always include a clear pathway to reach your provider when questions or concerns arise. This is a fundamental part of how we structure care at Rewind.

Side Effects by Dosing Phase

Understanding what to expect at each dose level helps patients prepare and reduces anxiety about normal adjustment symptoms.

Dose	Duration	What to Expect	Notes
0.25 mg	Weeks 1–4	Mild appetite reduction, possible mild nausea. Many patients notice minimal side effects.	Initiation dose — not therapeutic. Purpose is acclimation.
0.5 mg	Weeks 5–8	Appetite suppression becomes more noticeable. Nausea may increase briefly. Some patients report constipation starting here.	First dose increase is where most patients first notice GI effects.
1.0 mg	Weeks 9–12	Meaningful weight loss typically begins. GI side effects may briefly recur but are usually milder than the initial onset.	Many patients stabilize well at this dose.
1.7 mg	Weeks 13–16	Continued appetite reduction. GI symptoms from this increase are generally less pronounced if titration has been followed properly.	Some patients achieve target results here and do not need to escalate further.
2.4 mg	Weeks 17+	Maximum therapeutic dose. Peak appetite suppression and metabolic benefit. Side effects at this level are generally manageable if earlier titration was tolerated well.	Not all patients require the full 2.4 mg dose to achieve meaningful results.

Important: These timelines represent a standard protocol. Your provider may adjust the pace based on your individual tolerance. Dose increases should never be forced if side effects at the current dose have not adequately resolved.

Semaglutide vs Tirzepatide: Side Effect Comparison

Patients often ask how semaglutide side effects compare to tirzepatide (Mounjaro/Zepbound). Both are GLP-1-based medications, but tirzepatide is a dual GIP/GLP-1 agonist, which creates a somewhat different side effect profile.

Side Effect	Semaglutide (2.4 mg)	Tirzepatide (15 mg)
Nausea	20–30%	18–28%
Diarrhea	10–15%	12–17%
Constipation	10–15%	6–10%
Vomiting	8–12%	8–12%
Headache	10–14%	8–12%
Injection site reactions	3–5%	3–7%
Discontinuation due to side effects	6–7%	4–7%

The overall tolerability of both medications is comparable. Neither is consistently “easier” to tolerate across all patients. Individual response varies significantly, and the choice between semaglutide and tirzepatide should be based on the full clinical picture — not side effect profiles alone. For a deeper comparison, read our full guide on the difference between tirzepatide and semaglutide.

How Rewind Monitors Patients During Treatment

Medical supervision is not a marketing phrase — it is the structural difference between a safe, optimized treatment experience and an unsupervised one. Here is what ongoing monitoring looks like at Rewind Anti-Aging of Miami.

Regular provider check-ins. Patients have scheduled touchpoints with their provider throughout treatment. These are not optional wellness calls. They are clinical evaluations of tolerance, progress, and any emerging concerns. Dose adjustments, dietary guidance, and side effect management are addressed in real time.

Baseline and ongoing lab work. Before initiating treatment, we run comprehensive labs through our diagnostic testing program to establish baseline metabolic, thyroid, liver, kidney, and lipid markers. Labs are repeated at intervals throughout treatment to monitor for any changes that require intervention.

Individualized dose titration. Not every patient follows the same titration timeline. Some patients tolerate rapid titration. Others need additional time at a given dose. We adjust the schedule based on individual response — not a one-size-fits-all protocol.

Nutritional and body composition tracking. Monitoring weight alone is insufficient. We track body composition to ensure patients are losing fat — not disproportionate amounts of lean muscle. This data informs protein recommendations, exercise guidance, and dosing decisions.

Clear communication pathways. Patients have direct access to their care team between scheduled visits. If a side effect question arises on a Tuesday evening, you should not have to wait until your next appointment for guidance. Learn more about our full treatment process.

Who Should NOT Take Semaglutide

Semaglutide is not appropriate for everyone. The following are established contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC). GLP-1 receptor agonists have caused thyroid C-cell tumors in rodent studies. While this has not been confirmed in humans, anyone with a personal or family history of MTC should not use semaglutide.
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This genetic condition increases the risk of MTC and is a firm contraindication.
• History of pancreatitis. Patients with a history of pancreatitis should discuss the risks carefully with their provider. In many cases, GLP-1 therapy is not recommended.
• Pregnancy or planned pregnancy. Semaglutide should be discontinued at least two months before a planned pregnancy. It is not approved for use during pregnancy or breastfeeding. For more on what happens when you stop semaglutide, including weight regain risk and transition strategies, see our detailed guide.
• Known hypersensitivity. Any prior allergic reaction to semaglutide or any component of its formulation is a contraindication.
• Severe gastrointestinal disease. Patients with gastroparesis, inflammatory bowel disease, or severe GI motility disorders should be evaluated carefully before initiating treatment.

A thorough medical evaluation before starting treatment is not optional — it is the minimum standard of care. This includes a detailed medical history, family history review, and baseline lab work. At Rewind, this evaluation is built into our intake process before any medication is prescribed.

Related Articles

• Semaglutide Cost: What You’ll Actually Pay
• Is Semaglutide the Same as Ozempic?
• Tirzepatide vs Semaglutide: Key Differences

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PubMed
2. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. PubMed
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PubMed
4. U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information. Revised 2023.

---

Considering semaglutide for weight loss? Rewind Anti-Aging of Miami offers medically supervised semaglutide programs with careful dose titration and ongoing monitoring. See our process, review patient results, or schedule a consultation →